Pharmaceuticals, Biotechnology and Life Sciences
The Finnish biotech is going back to shareholders with a fully covered offering, aiming to fund a pivotal Phase II trial in high-risk myelodysplastic syndrome — and postponing its AGM for reasons that are anything but routine
A structural reorganization and a key appointment reveal a company that has moved beyond proving itself and is now building for dominance
The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
CEO of Leica Microsystems, a Danaher company — one of the few life sciences representatives in a room otherwise dominated by automotive and industrial giants.
A wave of oncology M&A, targeted mid-cap acquisitions, and cautious earnings guidance suggests pharma is entering a new capital discipline cycle. Here’s what investors should watch.
UK-based Hikma Pharmaceuticals posted higher annual revenue and strong performance in its injectables segment, but investors reacted negatively to its outlook, sending shares to a three-year low.
Gilead Sciences has agreed to acquire cancer therapy developer Arcellx Inc. in a transaction valued at up to $7.8 billion, deepening its footprint in cell therapy for blood cancers
The global drug discovery network ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its Board, reinforcing leadership across scientific programming and early career initiatives,
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental…